No abstract available
Keywords:
antiresorptive treatments; axial spondyloarthritis (AxSpA); diabetes and obesity; mendelian randomization; osteoporosis; primary hyperparathyroidism; renal osteodystrophy; serum bone markers.
Grants and funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. JMD-T was supported by a “Sara Borrell” postdoctoral contract (CD19/00055) funded by the Spanish Ministry of Science, Innovation and Universities, Carlos III Health Institute and co-funded by the European Regional Development Fund. AYS was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers KL2TR003108 and UL1TR003107. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.